CMPS — COMPASS Pathways plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1816590 ·
Last close
$7.98
Market Cap
$1.13B
52W High
$15.87
52W Low
$4.88
ADV30
3,349,039
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -54,389,000 | -9,831,000 | 519,096,000 | 443,979,000 | 377,029,000 |
| Jun 2026 | 0 | — | -49,789,000 | -253,794,000 | 504,561,000 | 433,295,000 | 420,028,000 |
| Mar 2026 | 0 | — | -40,427,000 | 91,202,000 | 531,739,000 | 466,010,000 | 205,052,000 |
| Dec 2025 | 0 | — | -58,864,000 | -93,878,000 | 210,349,000 | 149,608,000 | 263,197,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-176,799,000
Investing CF
—
Financing CF
$433,292,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.49
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-995,017,000
Inventory
—
Receivables
$15,205,000
ST Investments
—
EBIT TTM
$-264,231,000
Pretax Income TTM
$-269,821,000
Interest Exp TTM
$5,590,000
Analysts
16
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -175,290,000 | -287,862,000 | 210,349,000 | 263,197,000 | -52,848,000 | -157,240,000 |
| Dec 2024 | 0 | -157,108,000 | -155,122,000 | 213,666,000 | 58,971,000 | 154,695,000 | -119,186,000 |
| Dec 2023 | 0 | -124,044,000 | -118,464,000 | 275,987,000 | 50,243,000 | 225,744,000 | -97,376,000 |
| Dec 2022 | 0 | -95,979,000 | -91,505,000 | 197,294,000 | 16,014,000 | 181,280,000 | -105,451,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$9,061,000
NetIncome TTM
$-394,187,000
OpCashFlow TTM
—
Assets (Latest)
$504,561,000
Forward EPS
$-1.43
Max Pain — expiry 2026-12-18
max pain strike: $11.00 · spot: $8.12 · call oi: 1,465 · put oi: 6,304
Expected Move to 2026-12-18:
±$1.45
(17.86%) —
implied range
$6.67 –
$9.57
· ATM straddle on $8.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HROW | HARROW, INC. | $1.11B | $29.52 | — |
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | $1.09B | $7.28 | — |
| OPK | OPKO HEALTH, INC. | $1.20B | $1.62 | — |
| SLNCF | Silence Therapeutics plc | $1.22B | $6.53 | — |
| NKTR | NEKTAR THERAPEUTICS | $1.23B | $35.91 | — |
News headlines (Yahoo Finance, 1h cache)
COMPASS Pathways (CMPS) Could Be 62% Undervalued As FDA Filing Sharpens The Case
2026-11-12 20:13 · Yahoo
Compass Pathways Completes FDA Application for Psilocybin Therapy, Prepares for Launch
2026-11-12 11:13 · Yahoo
Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th
2026-11-11 11:30 · Yahoo
Compass Pathways PLC (CMPS) (Q3 2026) Earnings Call Highlights: $444 Million Cash Runway, FDA ...
2026-11-11 05:06 · Yahoo
Compass Pathways could secure US approval for depression drug by early 2027, Jefferies says
2026-11-09 19:00 · Yahoo
Compass Pathways stock gains on FDA filing for depression drug
2026-11-09 18:09 · Yahoo
Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression
2026-11-09 11:30 · Yahoo
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-05 21:30 · Yahoo
Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
2026-11-04 11:30 · Yahoo
How Investors May Respond To COMPASS Pathways (CMPS) Smaller Loss And FDA Progress
2026-11-04 06:16 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.